An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy

• Published in: Asian journal of andrology Vol. 17; no. 1; pp. 61 - 67
• Main Authors: Bai, Wen-Jun, Li, Hong-Jun, Dai, Yu-Tian, He, Xue-You, Huang, Yi-Ran, Liu, Ji-Hong, Sorsaburu, Sebastian, Ji, Chen, Jin, Jian-Jun, Wang, Xiao-Feng
• Format: Journal Article
• Language: English
• Published: China Medknow Publications and Media Pvt. Ltd 01.01.2015; Medknow Publications & Media Pvt. Ltd; Medknow Publications & Media Pvt Ltd; Wolters Kluwer Medknow Publications
• Subjects: Adult; Asian People; China; Comparative analysis; Cross-Over Studies; Dosage and administration; Dose-Response Relationship, Drug; Drug therapy; Erectile Dysfunction - drug therapy; Erectile Dysfunction - physiopathology; Erectile Dysfunction - psychology; erectile dysfunction; patient preference; phosphodiesterase 5 inhibitors; Health aspects; Humans; Impotence; Male; Middle Aged; Original; Phosphodiesterase 5 Inhibitors - adverse effects; Phosphodiesterase 5 Inhibitors - pharmacology; Phosphodiesterase 5 Inhibitors - therapeutic use; Phosphodiesterases; Quality of Life - psychology; Sexual Behavior - drug effects; Sexual Behavior - physiology; Sildenafil; Sildenafil Citrate - adverse effects; Sildenafil Citrate - pharmacology; Sildenafil Citrate - therapeutic use; Surveys and Questionnaires; Tadalafil; Tadalafil - adverse effects; Tadalafil - pharmacology; Tadalafil - therapeutic use; Treatment Outcome; China

The study was to compare treatment preference, efficacy, and tolerability of sildenafil citrate (sildenafil) and tadalafil for treating erectile dysfunction (ED) in Chinese men naοve to phosphodiesterase 5 (PDE5) inhibitor therapies. This multicenter, randomized, open-label, crossover study evaluate...